Displaying drugs 10226 - 10250 of 12433 in total
APR-548
APR-548 is an analog of eprenetapopt and a reactivator of mutant p53.
Investigational
Matched Description: … APR-548 is an analog of [eprenetapopt] and a reactivator of mutant p53. …
Brilaroxazine
Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder...
Investigational
Matched Description: … As of May 2015, it is in phase III clinical trials for schizophrenia. ... Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major ... investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of …
5alpha-androstane-3beta,17alpha-diol
5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite of testosterone with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.
Experimental
Matched Description: … of [testosterone] with androgenic activity. ... It has been implicated as a regulator of gonadotropin secretion. ... 5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite …
CTA018
CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D...
Investigational
Matched Description: … CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin ... of vitamin D) and a potent activator of vitamin D signaling pathways. ... This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown …
GSK-945237
GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237...
Investigational
Matched Description: … a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology ... Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.). ... Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of …
Demcizumab
Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Investigational
Matched Description: … Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. …
Amediplase
Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. [MeSH]
Investigational
Matched Description: … A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. ... Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the …
EW-A-401
EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new...
Investigational
Matched Description: … gene, and to promote the growth of new blood vessels. ... transcription factor, a protein that regulates expression of genes. ... This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A …
PMI-001
PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
Investigational
Matched Description: … It is an extract of the roots of an undisclosed perennial shrub which interferes with the production ... of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis …
Eperisone
Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries...
Investigational
Matched Description: … effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex ... antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of …
Adlinacogene civaparvovec
Adlinacogene civaparvovec is an investigational in vivo genome editing therapeutic product. It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX. Developed by Sangamo Therapeutics Inc., it is being investigated...
Experimental
Matched Description: … copy of the F9 gene, which controls the production of Factor IX. ... It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a ... [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia …
Tigapotide
Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid.
Investigational
Matched Description: … Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of ... the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid …
Cimlanod
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Matched Description: … Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of ... Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers). …
Egaptivon pegol
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.[A3290, A259053] Egaptivon pegol is a therapeutic...
Investigational
Matched Description: … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von ... , and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. ... Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute …
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to ... the treatment of various solid tumors. ... DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for …
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
Matched Description: … in the brain of Alzheimer's disease patients. ... CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. ... It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques …
Calanolide A
Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared...
Investigational
AVI-4557
AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs. Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and...
Investigational
Matched Description: … approximately half of currently marketed drugs. ... anxiety, cancer, and a number of other serious conditions. ... metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of …
SYNB1891
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Matched Description: … cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. ... SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce ... [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 …
Eniluracil
Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety...
Investigational
Matched Description: … , gastric, head and neck, ovarian and basal cell cancer of the skin. ... 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in ... GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of …
Zanapezil
Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
Investigational
Isothipendyl
Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.
Experimental
Befunolol
Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Experimental
Matched Description: … It is currently in experimental status, and is being tested for the management of open angle glaucoma …
PLN-74809
PLN-74809 is a small-molecule that dually inhibits both αvβ6 and αvβ1 to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) . The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in...
Investigational
Matched Description: … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and ... In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID ... Therapeutics recently raised $100 million in Series C financing to support further clinical development of …
Chlorproguanil
Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.
Investigational
Matched Description: … It is a dichloro-derivative of chloroguanide. ... Chlorproguanil has been used in trials studying the treatment of MALARIA. …
Displaying drugs 10226 - 10250 of 12433 in total